NCT05265299View on ClinicalTrials.gov

Trial to Determine Effective Aspirin Dose in COPD

PHASE3RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Aspirin 81mg

Aspirin 81mg once daily

DRUG

Aspirin 162 mg

Aspirin 162 mg once daily

DRUG

Aspirin 325mg

Aspirin 325mg once daily

Trial Locations (1)

21224

RECRUITING

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Johns Hopkins University

OTHER